IGC Announces Issuance of Second Patent for the Treatment of Alzheimer’s Using THC
21 Septembre 2022 - 12:00PM
Business Wire
India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE
American: IGC) announced today that the United States Patent and
Trademark Office (“USPTO”) issued a second patent (#11,446,276) for
the treatment of Alzheimer’s disease entitled “Extreme low dose THC
as a therapeutic and prophylactic agent for Alzheimer’s
disease.”
The original patent application was initiated by the University
of South Florida (“USF”) and filed on July 30, 2015. On May 25,
2017, IGC entered into an exclusive license agreement with USF with
respect to the patent application and the associated research
conducted on Alzheimer’s disease. On January 9, 2020, the patent
application was modified by the Company. Separately, on July 22,
2021, IGC announced the grant of the first patent (11,065,225) for
some of that research and work. This new patent is for a
continuation of that work.
The Company’s subsidiary, IGC Pharma, used some of the research
to develop an oral formulation, IGC-AD1. Based on the USF research
on Alzheimer’s cell lines, subject to further testing and clinical
trials, testing indicates that on a dose dependent manner, the
active agents in IGC-AD1 may ameliorate Aß plaque and decrease
ptau, a phosphorylated protein responsible for tangles in neurons.
Plaques and tangles are key hallmarks of Alzheimer’s disease.
Further, testing in an Alzheimer’s mouse model showed that it
improved memory as demonstrated in a Morris Water Maze test.
Based on these promising results, we initiated a Phase 1 study
on safety and tolerability and in that study discovered that
IGC-AD1 at specific dosing regimens had the potential to modify
agitation and other neuropsychiatric symptoms in patients with
Alzheimer’s dementia. Encouraged by this, our short term focus
shifted to further testing IGC-AD1 as a therapeutic for treating
neuropsychiatric synmptoms in Alzheimer’s, more specifically
agitation. The Company recently filed a Phase 2 protocol with the
U.S. Food and Drug Administration (“FDA”) for further clinical
testing of the efficacy of IGC-AD1 on agitation in mild to severe
Alzheimer’s.
Currently, there are no FDA approved pharmacological treatments
for agitation in dementia from Alzheimer’s and about 70% of
Alzheimer’s patients suffer from agitation/aggressiveness. The
Company is hopeful that, subject to further trials and FDA
approval, IGC-AD1 can provide relief for some of the over 55
million Alzheimer’s patients worldwide.
About IGC:
IGC has two segments: Life Sciences and Infrastructure. The
Company is based in Maryland, U.S.A.
Forward-looking Statements: This press release contains
forward-looking statements. These forward-looking statements are
based largely on IGC’s expectations and are subject to several
risks and uncertainties, certain of which are beyond IGC’s control.
Actual results could differ materially from these forward-looking
statements as a result of, among other factors, the Company’s
failure or inability to commercialize one or more of the Company’s
products or technologies, including the products or formulations
described in this release, or failure to obtain regulatory approval
for the products or formulations, where required; general economic
conditions that are less favorable than expected, including as a
result of the ongoing COVID-19 pandemic; the FDA’s general position
regarding cannabis- and hemp-based products; and other factors,
many of which are discussed in IGC’s SEC filings. IGC incorporates
by reference the human trial disclosures and Risk Factors
identified in its Annual Report on Form 10-K filed with the SEC on
June 23, 2022, and Quarterly Report on Form10-Q, filed with SEC on
August 5, 2022, as if fully incorporated and restated herein. In
light of these risks and uncertainties, there can be no assurance
that the forward-looking information contained in this release will
occur.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220921005448/en/
Claudia Grimaldi (301-983-0998)
IGC Pharma (AMEX:IGC)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
IGC Pharma (AMEX:IGC)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024